Emory Healthcare has completed robotic peripheral endovascular procedures using Microbot Medical's (NASDAQ: MBOT) LIBERTY Endovascular Robotic System, according to a company statement. The procedures included the first robotic prostatic artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.

Dr. Zachary L. Bercu, an interventional radiologist at Emory Healthcare, performed the first robotic prostate artery embolization using the LIBERTY system. The procedure treats enlarged prostate by blocking blood supply to shrink the tissue. Published research indicates benign prostatic hyperplasia affects approximately 40 million men in the United States.

The same team completed the first robotic Yttrium-90 radioembolization mapping for liver cancer at Emory using the handheld robotic system. The Y-90 procedure involves injecting radioactive beads into blood vessels that supply tumors, delivering targeted radiation while minimizing damage to healthy tissue.

The LIBERTY System received FDA clearance as a single-use, remotely operated robotic system for peripheral endovascular procedures. The device aims to provide precise vascular navigation while reducing radiation exposure and physical strain during procedures.

Microbot Medical began a limited market release of the LIBERTY system in November 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026. The company's CEO Harel Gadot stated the procedures at Emory demonstrate the system's potential benefits for clinicians and patients.

Emory Healthcare operates 11 hospitals with 3,028 licensed patient beds and more than 3,800 physicians across metro Atlanta and Georgia. Microbot Medical is a commercial-stage medical device company focused on endovascular robotic technology.